azathioprine has been researched along with Microsatellite Instability in 6 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Microsatellite Instability: The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
Excerpt | Relevance | Reference |
---|---|---|
" Prolonged treatment with immunosuppressants including azathioprine (Aza), a thiopurine prodrug, has been suggested as a risk factor for the development of late onset leukemias/lymphomas displaying a microsatellite instability (MSI) phenotype, the hallmark of a defective MMR system." | 7.81 | Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model. ( Beaugerie, L; Bodo, S; Brousse, N; Buhard, O; Capel, C; Chalastanis, A; Collura, A; Cuillières-Dartigues, P; Dinard, L; Dumont, S; Duval, A; Fabiani, B; Fléjou, JF; Lafitte, P; Ledent, T; Muleris, M; Penard-Lacronique, V; Sourrouille, I; Svrcek, M; Wanherdrick, K, 2015) |
" Prolonged treatment with immunosuppressants including azathioprine (Aza), a thiopurine prodrug, has been suggested as a risk factor for the development of late onset leukemias/lymphomas displaying a microsatellite instability (MSI) phenotype, the hallmark of a defective MMR system." | 3.81 | Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model. ( Beaugerie, L; Bodo, S; Brousse, N; Buhard, O; Capel, C; Chalastanis, A; Collura, A; Cuillières-Dartigues, P; Dinard, L; Dumont, S; Duval, A; Fabiani, B; Fléjou, JF; Lafitte, P; Ledent, T; Muleris, M; Penard-Lacronique, V; Sourrouille, I; Svrcek, M; Wanherdrick, K, 2015) |
"To investigate (i) whether loss of MMR protein expression and microsatellite instability are over-represented in squamous cell carcinomas (SCCs) from OTRs on azathioprine compared with SCCs from immunocompetent patients, and (ii) whether the MSH2 -6 exon 13 polymorphism is over-represented in OTRs with skin cancer on azathioprine." | 3.76 | Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. ( Cerio, R; Harwood, CA; Karran, P; McGregor, JM; Perrett, CM; Warwick, J, 2010) |
"Most untreated Msh2(WT) and Msh2(+/)⁻ mice remained asymptomatic and alive at 250 days of age, whereas azathioprine-treated Msh2(WT) and Msh2(+/)⁻ mice developed lymphomas and died prematurely (median survival of 71 and 165 days of age, respectively)." | 3.76 | Azathioprine-induced carcinogenesis in mice according to Msh2 genotype. ( Antoine, N; Buhard, O; Chalastanis, A; Defaweux, V; Dumont, S; Duval, A; Fabiani, B; Fléjou, JF; Muleris, M; Penard-Lacronique, V; Renault, I; Svrcek, M; Te Riele, H; Tubacher, E, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bodo, S | 2 |
Svrcek, M | 3 |
Sourrouille, I | 1 |
Cuillières-Dartigues, P | 1 |
Ledent, T | 1 |
Dumont, S | 3 |
Dinard, L | 1 |
Lafitte, P | 1 |
Capel, C | 1 |
Collura, A | 1 |
Buhard, O | 2 |
Wanherdrick, K | 1 |
Chalastanis, A | 2 |
Penard-Lacronique, V | 2 |
Fabiani, B | 2 |
Fléjou, JF | 3 |
Brousse, N | 1 |
Beaugerie, L | 2 |
Duval, A | 3 |
Muleris, M | 3 |
Kirchgesner, J | 1 |
Dartigues, P | 1 |
Lascols, O | 1 |
Seksik, P | 1 |
Cosnes, J | 1 |
Wisgerhof, HC | 1 |
Hameetman, L | 1 |
Tensen, CP | 1 |
Morreau, H | 1 |
de Fijter, JW | 1 |
Bouwes Bavinck, JN | 1 |
Willemze, R | 1 |
de Gruijl, FR | 1 |
Perrett, CM | 1 |
Harwood, CA | 1 |
McGregor, JM | 1 |
Warwick, J | 1 |
Cerio, R | 1 |
Karran, P | 1 |
Defaweux, V | 1 |
Antoine, N | 1 |
Renault, I | 1 |
Tubacher, E | 1 |
Te Riele, H | 1 |
Kuehn, F | 1 |
Klar, E | 1 |
Bliemeister, A | 1 |
Linnebacher, M | 1 |
6 other studies available for azathioprine and Microsatellite Instability
Article | Year |
---|---|
Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model.
Topics: Adult; Aged; Animals; Azathioprine; Disease Models, Animal; DNA Mismatch Repair; Dose-Response Relat | 2015 |
Azathioprine May Not be Associated With Development of Colorectal Tumors With Microsatellite Instability in Patients With Inflammatory Bowel Disease.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Colorectal Neoplasms; Female; Humans; Inflammatory Bow | 2016 |
Azathioprine-induced microsatellite instability is not observed in skin carcinomas of organ transplant recipients.
Topics: Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA, Neoplasm; Graft Rejection; Human | 2009 |
Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients.
Topics: Adaptor Proteins, Signal Transducing; Azathioprine; Base Pair Mismatch; Biomarkers, Tumor; Carcinoma | 2010 |
Azathioprine-induced carcinogenesis in mice according to Msh2 genotype.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Azathioprine; Carcinogens; Disease M | 2010 |
Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Autoantigens; Case-Control Studies; Female; Frameshift Mutation; Gen | 2015 |